Morgan Stanley set a $168.00 price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Wednesday. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
Several other equities research analysts have also recently commented on JAZZ. Stifel Nicolaus increased their price objective on Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a buy rating in a research report on Wednesday, August 8th. Mizuho dropped their price objective on Jazz Pharmaceuticals to $157.00 and set a neutral rating on the stock in a research report on Tuesday, November 20th. BMO Capital Markets increased their price objective on Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an outperform rating in a research report on Wednesday, August 8th. ValuEngine cut Jazz Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, November 7th. Finally, Zacks Investment Research reissued a hold rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, November 13th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $189.76.
Jazz Pharmaceuticals stock opened at $151.20 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29. Jazz Pharmaceuticals has a one year low of $130.15 and a one year high of $184.00. The firm has a market cap of $8.90 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 0.88 and a beta of 1.06.
In other news, Director Seamus Mulligan bought 50,000 shares of the company’s stock in a transaction on Thursday, November 15th. The shares were acquired at an average cost of $144.56 per share, with a total value of $7,228,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 10,130 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $168.76, for a total value of $1,709,538.80. Following the completion of the transaction, the director now directly owns 19,884 shares in the company, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders sold 16,730 shares of company stock worth $2,773,011 over the last three months. Insiders own 3.90% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Stratos Wealth Partners LTD. purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $106,000. Riverhead Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $113,000. Financial Enhancement Group LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $140,000. Tiverton Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $198,000. Finally, Paloma Partners Management Co purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $224,000. 92.30% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.